Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.39 |
| ▸ | FFAR2 | O15552 | 3/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.33 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8740731 | 0.85 | RAF1 (0.44) | LRRK2 | |
| SCHEMBL22105416 | 0.79 | LRRK2 (0.39) | LRRK2FFAR2HRH4 | |
| SCHEMBL19510827 | 0.79 | MCHR1 (0.38) | LRRK2FFAR2MCHR1JAK3HRH4 | |
| SCHEMBL15831972 | 0.79 | MBOAT4 (0.38) | LRRK2FFAR2JAK3HRH4MBOAT4 | |
| SCHEMBL25510477 | 0.77 | LRRK2 (0.38) | LRRK2FFAR2JAK3HRH4 | |
| SCHEMBL16334172 | 0.76 | LRRK2 (0.39) | LRRK2FFAR2JAK3HRH4MBOAT4 | |
| SCHEMBL15831963 | 0.76 | LOX (0.39) | LRRK2FFAR2MCHR1JAK3HRH4 | |
| SCHEMBL15831922 | 0.76 | HRH4 (0.40) | LRRK2HRH4MBOAT4CNR2 | |
| SCHEMBL6607678 | 0.75 | FFAR4 (0.43) | — | |
| SCHEMBL15831965 | 0.74 | LOX (0.41) | LRRK2FFAR2MCHR1JAK3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577373-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | LRRK2 269/4885FFAR2 3861/4885MCHR1 3186/4885 |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | LRRK2 269/4885FFAR2 3861/4885MCHR1 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.